4/11/2014

Wisconsin-based molecular-diagnostics-maker Exact Sciences secured $137.7 million in net proceeds from a public shares offering. The company said proceeds from the offering would go toward general-corporate and working-capital purposes, including FDA application and subsequent commercialization of the firm's Cologuard assay.

Related Summaries